<DOC>
	<DOCNO>NCT00949598</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use letrozole may fight breast cancer block uptake estrogen . Tamoxifen citrate may fight breast cancer block use estrogen tumor cell . It yet know whether letrozole tamoxifen citrate effective give surgery treat old woman breast cancer . PURPOSE : This randomized phase III trial study letrozole see well work compare tamoxifen citrate treat old postmenopausal woman undergo surgery breast cancer .</brief_summary>
	<brief_title>Letrozole Tamoxifen Citrate Treating Older Postmenopausal Women Undergoing Surgery Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Investigate change Ki67 PCNA postmenopausal woman estrogen receptor-positive ( ER+ ) breast cancer 4 month treatment letrozole v tamoxifen citrate . Secondary - Compare response 4 month therapy . - Define resistant form cancer patient treat regimen . - Define molecular signature predictive sensitivity resistance ER+ breast adenocarcinoma gene serum protein profile . - Search serum protein profile predictive recurrence-free interval . OUTLINE : Patients randomize 1 2 intervention arm . - Arm I : Patients receive oral letrozole daily 16 week . - Arm II : Patients receive oral tamoxifen citrate daily 16 week . Patients arm undergo surgery . Blood tumor tissue sample collect baseline completion neoadjuvant therapy change Ki67 PCNA serum protein profile analysis . After completion study therapy , patient follow every 6 month 3 year , year 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast adenocarcinoma Clinically T2 tumor and/or &gt; 1 cm echography Estrogen receptor ( ER ) positive &gt; 10 % tumor cell positive No ERnegative disease No prior breast cancer No metastatic inflammatory breast adenocarcinoma PATIENT CHARACTERISTICS : Postmenopausal No cardiac function could contraindicate surgery medical treatment ( e.g. , radiotherapy and/or chemotherapy ) No prior malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No mental incapacitation would preclude consent No contraindication tamoxifen citrate letrozole PRIOR CONCURRENT THERAPY : More 8 day since prior hormonereplacement therapy treatment ( i.e. , phytoestrogen ) menopause No concurrent therapy would modify expression gene regulate estrogen No concurrent participation another clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>